Dr. Altomare on Investigational Agents in ITP

Ivy P. Altomare, MD, discusses investigational agents in immune thrombocytopenia.

Ivy P. Altomare, MD, associate professor of medicine, Department of Medicine, Duke University School of Medicine, and medical oncologist, Duke Cancer Network, discusses investigational agents in immune thrombocytopenia (ITP).

There are many emerging classes of agents in the ITP pipeline including neonatal Fc receptor (FcRn) inhibitors, BTK inhibitors, and low-dose decitabine, says Altomare. The FcRn inhibitors are administered intravenously or subcutaneously.

Phase 2 data presented at the 2019 ASH Annual Meeting demonstrated efficacy with the FcRn inhibitors efgartigimod (ARGX-113) and rozanolixizumab (UCB7665) in ITP, explains Altomare. As such, phase 3 clinical trials with these agents are ongoing.

FcRn inhibitors can target the FcRn pathway, which is a key part of preserving and recycling immunoglobulin, says Altomare. Inhibition of the FcRn pathway can degrade an IgG molecule, thus making these drugs potentially effective in treating patients with autoimmune diseases, such as ITP.

Related Videos
Jeffery Zonder, MD
Julie Renee Brahmer, MD
Brian Mitzman, MD, FACS, FCCP
Bradley W. Christensen, MD
Anne Chiang, MD, PhD, associate professor, medical oncology, Yale School of Medicine, associate cancer center director, Clinical Initiatives, Smilow Cancer Hospital, Yale Cancer Center
Dario R. Roque, MD, assistant professor of Obstetrics and Gynecology (Gynecologic Oncology), Northwestern University’s Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern Medicine
Natalie S. Callander, MD
Brian Henick, MD
Abhinav Deol, MD
Veronika Bachanova, MD, PhD
Related Content